Related references
Note: Only part of the references are listed.Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors A single-center experience
Aneet Kaur et al.
MEDICINE (2019)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
Jennifer Dine et al.
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING (2017)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Entering the mainstream of cancer treatment
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the Interchangeability of PPS and KPS in Prognostic Tools
Ingrid de Kock et al.
JOURNAL OF PALLIATIVE CARE (2013)
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
Mary L. Disis
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Share Paper
